13F Holdings
中文EN

AVXL ANAVEX LIFE SCIENCES CORP.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1314052 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY73.0%
TTM EPS YoY75.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-12.8%
ROA-11.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6.4%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.25x
Accruals ratio14.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue—————
R&D expense$37.59M$41.84M$43.72M$37.92M$32.98M
SG&A expense$13.82M$11.04M$12.05M$13.07M$9.02M
Operating income-$51.41M-$52.88M-$55.76M-$50.99M-$42.00M
Pretax income-$46.38M-$43.00M-$47.50M-$47.62M-$37.64M
Net income-$46.38M-$43.00M-$47.51M-$47.98M-$37.91M
EPS (basic)-0.54-0.52-0.60-0.62-0.54
EPS (diluted)-0.54-0.52-0.60-0.62-0.54
Weighted avg. shares (diluted)85.29M83.47M79.79M76.91M69.80M
Banking
Net interest income$4.68M$7.32M$6.52M$947,000$26,000
Balance sheet
Cash & equivalents$102.58M$132.19M$151.02M$149.16M$152.11M
Total assets$103.81M$135.57M$154.39M$152.71M$161.62M
Current liabilities————$10.80M
Total liabilities$8.95M$15.30M$12.53M$10.21M$10.80M
Shareholders' equity$94.87M$120.26M$141.85M$142.49M$150.82M
Shares outstanding86.67M84.80M82.07M77.94M75.92M
Cash flow statement
Operating cash flow-$39.04M-$30.81M-$27.79M-$24.24M-$30.38M
Financing cash flow$9.43M$11.97M$29.65M$21.29M$153.24M
Stock-based compensation$11.55M$9.44M$16.37M$18.38M$8.23M

Free plan shows the latest 5 periods; Pro shows all 21 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.